Actinium Pharmaceuticals (NYSE:ATNM) Lowered to “Sell” Rating by StockNews.com

Actinium Pharmaceuticals (NYSE:ATNM) was downgraded by equities researchers at StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Thursday.

Separately, HC Wainwright reiterated a “buy” rating and issued a $4.00 target price on shares of Actinium Pharmaceuticals in a report on Tuesday, April 1st. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $7.40.

Actinium Pharmaceuticals Stock Performance

ATNM stock opened at $1.30 on Thursday. The stock’s 50 day simple moving average is $1.27 and its 200 day simple moving average is $1.41. The company has a market cap of $40.55 million, a P/E ratio of -0.94 and a beta of -0.27. Actinium Pharmaceuticals has a fifty-two week low of $1.03 and a fifty-two week high of $10.24.

Institutional Trading of Actinium Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Wellington Management Group LLP bought a new position in Actinium Pharmaceuticals during the 3rd quarter valued at $112,000. XTX Topco Ltd purchased a new stake in shares of Actinium Pharmaceuticals in the third quarter valued at about $268,000. Barclays PLC lifted its position in shares of Actinium Pharmaceuticals by 323.0% during the third quarter. Barclays PLC now owns 42,935 shares of the company’s stock valued at $81,000 after purchasing an additional 32,784 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Actinium Pharmaceuticals by 3.0% during the third quarter. Geode Capital Management LLC now owns 686,153 shares of the company’s stock worth $1,290,000 after purchasing an additional 19,843 shares during the last quarter. Finally, Vontobel Holding Ltd. bought a new stake in Actinium Pharmaceuticals in the 4th quarter worth about $32,000. 27.50% of the stock is owned by institutional investors.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).